share_log

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $148

Benzinga Real-time News ·  Aug 11, 2022 09:08

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $152 to $148.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment